PSMA PET/CT has cemented its place as the standard of care for primary staging and restaging in the setting of prostate specific antigen (PSA) biochemical recurrence, guiding a new era in the management of prostate cancer [4]. The gene discussed is FOLH1; the disease is prostate carcinoma.